High-dose interleukin-2 therapy related adverse events and implications on imaging
High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma. IL-2 is able to promote CD8+ T cell and natural killer (NK) cell cytotoxicity to increase tumoricidal activity of the innate im...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Publishing House
2021-09-01
|
Series: | Diagnostic and Interventional Radiology |
Online Access: |
http://www.dirjournal.org/archives/archive-detail/article-preview/high-dose-interleukin-2-therapy-related-adverse-ev/54057
|